Launch Tech Co Ltd Stock
?
Your prediction
Financial data and news for Launch
sharewise wants to provide you with the best news and tools for Launch, so we directly link to the best financial data sources.
Financials
News
Ionis Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose to $268 million, with commercial revenue reaching $119 million, driven
A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
Key Points
- Interested in SpaceX? Here are five stocks we like better.
- SpaceX shares have fallen below their $135 IPO price, erasing over $1 trillion in implied market value amid concerns about
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
Key Points
- Interested in Celcuity, Inc.? Here are five stocks we like better.
- Celcuity won full FDA approval for gedatolisib, now branded REVTORPYK, in a specific advanced breast cancer
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Key Points
- Interested in Vera Therapeutics, Inc.? Here are five stocks we like better.
- Vera Therapeutics won accelerated FDA approval for TRUTAKNA (atacicept-vymj) to treat adults with primary
Rocket Lab Defies Gravity With $8B Buyout
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Rocket Lab agreed to acquire Iridium Communications in an estimated $8 billion cash-and-stock deal
Rocket Lab's NASA Win Tests Key Support After Sharp Pullback
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Rocket Lab’s latest NASA selection for three dedicated Electron launches reinforces its credibility with
The Biggest Opportunity From SpaceX’s IPO May Surprise You
Key Points
- Interested in Redwire Corporation? Here are five stocks we like better.
- The SpaceX IPO is more than four times oversubscribed, leaving an estimated $225 billion in sidelined capital to
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
Key Points
- Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better.
- Alnylam set new 2030 goals targeting 25% annual revenue growth and a 30% non-GAAP operating margin
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Key Points
- Interested in Arvinas, Inc.? Here are five stocks we like better.
- Arvinas is narrowing its pipeline focus after the first PROTAC approval, concentrating internal investment on
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Key Points
- Interested in Starfighters Space, Inc.? Here are five stocks we like better.
- Weiss Ratings analyst Chris Graebe argues the largest IPO gains go to investors who enter companies at the
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
Key Points
- Interested in IDEXX Laboratories, Inc.? Here are five stocks we like better.
- CEO Michael Erickson used a Stifel conference to highlight IDEXX’s long-term focus on diagnostics
AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Key Points
- Interested in AST SpaceMobile, Inc.? Here are five stocks we like better.
- Despite a setback in April when the BlueBird 7 satellite failed to reach the proper altitude and was
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric
Abeona Therapeutics Q1 Earnings Call Highlights
Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for
Archer Aviation Q1 Earnings Call Highlights
Archer Aviation (NYSE:ACHR) executives said the company is increasing investment across its civil air taxi, defense and aviation
Rekor Systems Q1 Earnings Call Highlights
Rekor Systems (NASDAQ:REKR) said its first-quarter results reflected early benefits from a broad cost-reduction effort, while management pointed to stronger margins, higher recurring revenue and a
ESAB Q1 Earnings Call Highlights
ESAB (NYSE:ESAB) reported what management described as a strong start to 2026, with record first-quarter sales and reaffirmed full-year guidance despite higher costs tied to the conflict in Iran
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough
Stoke Therapeutics Q1 Earnings Call Highlights
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year
Scholar Rock Q1 Earnings Call Highlights
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License
Defense Budget Expansion: 3 Mid-Cap Names in a Sweet Spot
In early April, the Trump administration proposed an increase in defense spending to $1.5 trillion for 2027. This was the largest such request in decades and would mark a 44% increase for the
Buyback Watch: KLA, Flutter, and Grab Move Fast as Their Stocks Swing
Despite putting up wildly different performances lately, big names across semiconductors, entertainment, and e-commerce are indicating significant confidence in their outlooks through recent